

# Clinical Outcome Assessment (COA) Instrument Management Services

## Preserving the Scientific Integrity of Evidera Measures

For nearly 30 years, Evidera has led the field in the design, development, validation and implementation of clinical outcomes assessments (COAs). We have deep expertise in developing patient-reported outcomes (PROs), clinician-reported outcomes (ClinROs), observer-reported outcomes (ObsROs), and performance outcomes (PerfOs) that meet regulatory and other stakeholder demands.

We now offer licensure and distribution of select Evidera developed COA instruments. Licensing from the same team of scientists and researchers who developed the instruments protects the scientific integrity of the measure, and ensures that the results obtained are reliable and relevant.

## Why choose Evidera to license your instrument?

### QUALITY

Broad use of validated questionnaires by multiple researchers helps establish an instrument as a benchmark for quality assessment.

### EXPERTISE

As the developers of the instrument, Evidera's team is best positioned to address questions about its use and ensure adoption of the most up-to-date versions and translations.

### INTEGRITY

Evidera's experts will ensure that the distributed instruments are used, scored, and properly translated.

### EASE

Evidera can facilitate complementary services such as additional translations, ePRO preparation, or validation for other applications and ensure proper process, documentation, and monitoring.

**30**

years experience  
designing COAs

**7**

COA instruments currently  
available for licensure

**200+**

publications related to  
patient-centered research in the  
past three years

**110+**

scientists and researchers  
dedicated to patient-centered  
research — one of the largest  
groups in the industry

## COAs Currently Available for Licensure



### RESPIRATORY

**Exacerbations of Chronic Pulmonary Disease (EXACT-PRO)** - Quantifies and measures exacerbations of chronic obstructive pulmonary disease (COPD)

**Evaluating Respiratory Symptoms of COPD (E-RS)** - Measures the effect of treatment on the severity of respiratory symptoms in stable COPD



### GASTROENTEROLOGY

**Crohn's Disease Patient-Reported Outcomes (CD-PRO)** - Evaluates treatment efficacy in adults with moderate to severe Crohn's disease

**Ulcerative Colitis Patient-Reported Outcomes (UC-PRO)** - Evaluates treatment efficacy in adults with moderate to severe ulcerative colitis



### NEUROLOGY

**Migraine Functional Impact Questionnaire (MFIQ)** - Evaluates the benefit of preventive treatments on functional outcomes for adults with migraine

**Migraine Physical Function Impact Diary (MPFID)** - Assesses the impact of migraine on physical functioning in adults with episodic migraine (EM) or chronic migraine (CM)



### DERMATOLOGY

**Psoriasis Symptom Inventory (PSI)** - Assesses symptom severity in chronic plaque psoriasis

## Evidera's Innovative Approach to Patient-Centered Research

- Created one of the few PRO instruments recommended for clinical use in an international clinical guidance document: COPD Assessment Test (CAT)
- Developed the first multi-sponsor PRO consortium: The EXACT-PRO Initiative
- Developed the first PRO instrument to achieve FDA PRO qualification: The EXACT
- Designed two of the first condition-specific utility indexes: Asthma Symptom Utility Index (ASUI) and Rhinitis Symptom Utility Index (RSUI)
- Partnered with the American Neurogastroenterology and Motility Society (ANMS) to develop the ANMS Gastroparesis Cardinal Symptom Index-Daily Diary (GCSI-DD), now an endpoint for clinical trials in diabetic and idiopathic gastroparesis

### Partner with Evidera

To learn more about licensing our COAs, visit

[evidera.com/coa-instrument-management-services/](https://evidera.com/coa-instrument-management-services/)

or email [info@evidera.com](mailto:info@evidera.com).